Kwiminyaka yakutshanje, unyango lokutyeba kakhulu kunye nohlobo lwe-2 yeswekile luye lwenziwa inkqubela phambili yenguqu. Ukulandela i-GLP-1 i-receptor agonists (umzekelo, i-Semaglutide) kunye ne-agonists ezimbini (umzekelo, iTirzepatide),Retatrutide(LY3437943), aI-agonist kathathu(GLP-1, GIP, kunye ne-glucagon receptors), ibonise ukusebenza okungazange kubonwe ngaphambili. Ngeziphumo ezimangalisayo ekunciphiseni ubunzima kunye nokuphuculwa kwe-metabolic, ithathwa njengonyango olunokubakho lwezifo ze-metabolic.
Indlela yokwenza
-
GLP-1 receptor kusebenze: Yandisa ukukhutshwa kwe-insulin, icinezela umdla wokutya, ilibazise ukukhupha isisu.
-
GIP receptor kusebenze: Yandisa iziphumo zokunciphisa i-glucose ye-GLP-1, iphucula uvakalelo lwe-insulin.
-
Ukusebenza kwe-Glucagon receptor: Ukukhuthaza inkcitho yamandla kunye ne-fat metabolism.
I-synergy yala ma-receptors amathathu ivumela i-Retatrutide ukuba idlule iziyobisi ezikhoyo ekulahlekeni kwesisindo kunye nokulawula i-glycemic.
Idatha yovavanyo lwezonyango (iSigaba II)
KwiUlingo lweSigaba sesi-II kunye nezigulane ezingama-338 ezityebileyo / ezityebileyo, I-Retatrutide ibonise iziphumo ezithembisayo kakhulu.
Itheyibhile: Ukuthelekiswa kweRetatrutide vs. Placebo
| Idosi (mg/iveki) | Ukunciphisa ubunzima obuphantsi (%) | Ukunciphisa i-HbA1c (%) | Iziganeko ezimbi eziqhelekileyo |
|---|---|---|---|
| 1 mg | -7.2% | -0.9% | Isicaphucaphu, ukugabha kancinci |
| 4 mg | -12.9% | -1.5% | Isicaphucaphu, ukuphelelwa ngumdla |
| 8 mg | -17.3% | -2.0% | Ukungakhululeki kwe-GI, isifo sohudo esincinci |
| 12 mg | -24.2% | -2.2% | Isicaphucaphu, ukuphelelwa ngumdla, ukuqunjelwa |
| Indawo | -2.1% | -0.2% | Akukho tshintsho lubalulekileyo |
Ukubonwa kweDatha (Uthelekiso lokuNcitshiswa kobunzima)
Le tshathi yebha ilandelayo ibonisaukunciphisa ubunzima obuphakathikuzo zonke iidosi ezahlukeneyo zeRetatrutide xa kuthelekiswa ne-placebo:
Ixesha lokuposa: Sep-16-2025